Matinas BioPharma Holdings (MTNB) Accumulated Expenses (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Accumulated Expenses of $694000.0 for Q1 2026, down 41.14% year-over-year from $1.2 million in Q1 2025, and up 53.54% quarter-over-quarter from $452000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Accumulated Expenses (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Accumulated Expenses for 14 consecutive years, with $694000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 41.14% year-over-year to $694000.0; the TTM figure through Mar 2026 stood at $694000.0 (down 41.14% YoY), while the FY2025 annual figure was $452000.0, down 74.96% from the prior year.
- Accumulated Expenses advanced to $694000.0 in Q1 2026 per MTNB's latest filing, from $452000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $4.3 million in Q2 2022 and bottomed at $452000.0 in Q4 2025.
- Historically, Accumulated Expenses has averaged $1.6 million across 5 years, with a median of $1.4 million in 2023.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 593.76% — and 2025, when it sank 74.96%.
- Matinas BioPharma Holdings' Accumulated Expenses stood at $3.1 million in 2022, then plunged by 53.31% to $1.4 million in 2023, then gained by 24.74% to $1.8 million in 2024, then tumbled by 74.96% to $452000.0 in 2025, then jumped by 53.54% to $694000.0 in 2026.
- Business Quant data shows MTNB's Accumulated Expenses at $694000.0 in Q1 2026, $452000.0 in Q4 2025, and $564000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 504,000.00 |
| Mar 31, 2026 | 694,000.00 |
| Dec 31, 2025 | 452,000.00 |
| Sep 30, 2025 | 564,000.00 |
| Jun 30, 2025 | 795,000.00 |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 839,000.00 |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | 791,000.00 |
| Dec 31, 2022 | 3.10 Mn |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 4.29 Mn |
| Mar 31, 2022 | 1.84 Mn |
| Dec 31, 2021 | 2.85 Mn |
| Sep 30, 2021 | 2.89 Mn |